CRBP - CIK 0001595097
The table below shows Corbus Pharmaceuticals Holdings, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$64.49M | -$41.79M | -$36.10M | -$37.54M | -$48.18M | -$99.69M |
| Capital expenditure | $7.00K | $0.00 | $0.00 | $13.45K | $54.17K | $484.49K |
| Investing cash flow | -$1.64M | -$121.31M | $35.64M | $30.07M | -$73.42M | -$484.49K |
| Dividends paid | - | - | - | - | - |
Corbus Pharmaceuticals Holdings, Inc. reported operating cash flow of -$64.49M for fiscal year 2025. That is down 54.3% from -$41.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$27.80M (FY 2017) to -$64.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $77.43M | $166.58M | -$2.82M | -$533.62K | $60.82M | $154.87M |